STOCK TITAN

Kura Oncology (KURA) SEC Filings, Jan-Mar 2026

KURA NASDAQ

Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.

Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.

Rhea-AI Summary

Kura Oncology files its annual report highlighting a pivotal year in which the FDA approved KOMZIFTI (ziftomenib) on November 13, 2025 for adults with relapsed or refractory NPM1‑mutated AML who lack satisfactory alternatives. The company has transformed into a fully integrated commercial-stage organization, launching U.S. sales in November 2025 and co-promoting with Kyowa Kirin.

Kura estimates a U.S. market opportunity of about $350–$400 million annually for relapsed or refractory NPM1‑mutated AML and roughly $7.0 billion across frontline and relapsed or refractory AML. A broad menin inhibitor program spans multiple Phase 3 and Phase 1 combination trials in AML, plus an early program in GIST.

The company is also advancing next-generation menin inhibitors, including KO‑7246 for diabetes and cardiometabolic diseases, and darlifarnib, a next‑generation farnesyl transferase inhibitor in combinations across RCC, KRASG12C‑mutated NSCLC, CRC and PDAC. As of June 30, 2025, non‑affiliate equity had an aggregate market value of about $496.1 million, and 88,329,759 common shares were outstanding as of February 27, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
annual report
-
Rhea-AI Summary

Kura Oncology reported its first commercial revenue from KOMZIFTI (ziftomenib) alongside fourth quarter and full year 2025 results. KOMZIFTI, the first approved once-daily oral menin inhibitor for relapsed or refractory NPM1‑mutated AML, generated $2.1 million in net product revenue in Q4 2025 from about five weeks of sales.

Total Q4 2025 revenue was $17.3 million, driven by $15.2 million of collaboration revenue, down from $53.9 million a year earlier. Higher investment in development and commercialization increased R&D expenses to $64.4 million and SG&A to $39.1 million, resulting in a Q4 net loss of $81.0 million, compared with a $19.2 million loss in Q4 2024.

For full year 2025, net loss was $278.7 million. The company ended 2025 with $667.2 million in cash, cash equivalents and short-term investments and expects this, together with $180 million in anticipated collaboration payments, to fund its ziftomenib AML program through first topline Phase 3 KOMET‑017 frontline results, anticipated in 2028, and to support its broader pipeline into the fourth quarter of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
current report
-
Rhea-AI Summary

Kura Oncology reported an amendment to a Schedule 13G/A showing Armistice Capital, LLC and Steven Boyd beneficially own 4,936,000 shares of common stock, equal to 5.67% of the class as reported. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over those shares while the Master Fund disclaims beneficial ownership under its Investment Management Agreement. The filing is dated 02/17/2026 and notes an ownership reference date of 12/31/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
ownership
Rhea-AI Summary

State Street Corporation reported a passive ownership stake in Kura Oncology, Inc. common stock. As of 12/31/2025, State Street beneficially owned 4,931,090 shares, representing 5.7% of the outstanding common stock. All voting and dispositive authority is shared across its asset-management subsidiaries, with no sole power reported.

State Street certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Kura Oncology. The filing identifies several State Street Global Advisors entities as investment adviser affiliates involved in managing these holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
ownership
-
Rhea-AI Summary

Kura Oncology, Inc. has adopted amended and restated bylaws that significantly update its corporate governance rules for stockholder meetings, director nominations and board procedures. The changes refine who can call, postpone or adjourn meetings, adjust quorum and voting standards, and align notice provisions with Delaware law.

The bylaws tighten advance notice and disclosure requirements for stockholder proposals and director nominations, limit substitute nominees, and require proponents to provide detailed information and certifications. They also expand indemnification and expense advancement for directors and officers to the maximum extent allowed by law and enhance forum selection provisions, including a federal forum clause for Securities Act claims.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
current report
-
Rhea-AI Summary

Kura Oncology’s Chief Commercial Officer Brian T. Powl reported routine share sales related to tax withholding on vested restricted stock units. On January 27, 2026, he sold 4,842 and 1,572 shares of common stock at prices of $8.4606 and $8.4607 per share, respectively, as sell-to-cover transactions for RSUs granted on January 2, 2025 and January 2, 2024. Following these sales, he directly owned 183,275 shares of Kura Oncology common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider
Rhea-AI Summary

Kura Oncology, Inc. Chief Operating Officer Kathleen Ford reported a small stock sale related to tax withholding. On 01/27/2026, she sold 1,813 shares of common stock at $8.4607 per share in a transaction coded “S.”

The filing explains this was a sell-to-cover for taxes tied to the vesting of a restricted stock unit granted on 01/26/2022. After this transaction, Ford beneficially owned 153,560 shares of Kura Oncology common stock in direct form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider
-
Rhea-AI Summary

Kura Oncology Chief Medical Officer Mollie Leoni reported routine share sales tied to tax withholding on restricted stock units (RSUs). On January 27, 2026, she sold a total of 8,180 shares of Kura Oncology common stock at $8.4607 per share in four transactions classified as "sell-to-cover" for RSU vesting taxes.

After these sales, Leoni directly beneficially owned 267,274 shares of Kura Oncology common stock, indicating she retains a substantial equity position while satisfying tax obligations from prior RSU awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. senior vice president of finance and accounting Thomas James Doyle reported several small sales of common stock on January 27, 2026, each at $8.4607 per share. The transactions were sell-to-cover trades for taxes tied to vesting restricted stock units granted between 2022 and 2025.

After these sales, Doyle beneficially owns 145,167 Kura Oncology common shares directly and an additional 500 shares indirectly through his spouse’s 401(k) account, indicating he retains a substantial equity stake in the company following the tax-related transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider
Rhea-AI Summary

Kura Oncology, Inc. Chief Scientific Officer Francis Burrows reported a small sale of company stock in connection with tax withholding. On January 27, 2026, he sold 1,311 shares of common stock at $8.4607 per share in a sell-to-cover transaction for taxes tied to the vesting of a restricted stock unit granted on January 26, 2022.

After this transaction, Burrows beneficially owns 32,424 shares of Kura Oncology common stock, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider

FAQ

How many Kura Oncology (KURA) SEC filings are available on StockTitan?

StockTitan tracks 130 SEC filings for Kura Oncology (KURA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Kura Oncology (KURA)?

The most recent SEC filing for Kura Oncology (KURA) was filed on November 19, 2026.